graves ophthalmopathy

Showing NaN - NaN of 1

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Graves Ophthalmopathy Trial in Newcastle upon Tyne (Otelixizumab - low dose, Otelixizumab - medium low dose, Otelixizumab -

Terminated
  • Graves Ophthalmopathy
  • Otelixizumab - low dose
  • +5 more
  • Newcastle upon Tyne, United Kingdom
    GSK Investigational Site
Oct 8, 2020